As the number of cell and gene therapies expands, it's increasingly important for long-term patient data, explained Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health.
Fran Gregory, PharmD, MBA
Advertisement
Fran Gregory, PharmD, MBA, is the vice president of emerging therapies at Cardinal Health.
Articles by Fran Gregory, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
2
New Bill Makes CMS Enforcer in PBM, Pharmacy Relationship: A Q&A With Jesse Dresser, Esq
3
Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes
4
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
5